Due to the inhibitory effect of ACAT1 on PDC by acetylating PDH and PDH phosphatase, AH treatment could enhance PDC flux and oxidative phosphorylation to impair tumor growth, making ACAT1 a potential anti-tumor target. This evidence concerns the gene PDP1 and neoplasm.